Author

Maximilian Koch

Universitätsklinikum WürzburgPrimary ORCID profile (0009-0002-5069-519X · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Maximilian KochiD1 paper · University of Würzburg

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Alexander F. vom SteiniD· 1 shared Andreas SchlösseriD· 1 shared Aneeta Andrews· 1 shared Christoph ErbacheriD· 1 shared Guillermo Rodríguez‐RealiD· 1 shared Maximilian BreyeriD· 1 shared Michael J. HallekiD· 1 shared Natascha RoseniD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander F. vom SteinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Axon guidance deficits in a human sensory neuron model of Fabry disease

Christoph Erbacher, Aneeta Andrews, Till Sauerwein, Maximilian Breyer, Panagiota Arampatzi, Maximilian Koch, Stephanie Lamer, Tom Gräfenhan, Andreas Schlösser, Nurcan Üçeyler

This study models Fabry disease in human sensory neurons and finds axon guidance deficits and reduced neurite length due to Gb3 accumulation, with partial rescue by AGAL enzyme supplementation.

Experimental Neurology · Nov 21, 2025Peer-reviewedNeuroscience

Reduced CSF1R expression in myeloid cells has limited impact on chronic lymphocytic leukemia progression

Natascha Rosen, Guillermo Rodríguez‐Real, Viktoria Kohlhas, Thanh-Tung Truong, Alexander F. vom Stein, Maximilian Koch, Sebastian Reinartz, Sumiya Iqbal, Shaista Ilyas, Sanjay Mathur, Nina Reinart, Phuong‐Hien Nguyen, Michael J. Hallek

This study shows that reducing CSF1R expression in myeloid cells has limited impact on CLL progression, suggesting that targeting CSF1R alone may not be effective for therapy.

bioRxiv · Oct 7, 2025 · PreprintCancer Biology